Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis-Reference-Cited by-同舟云学术

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

Published:2009-02 Issue:2 Volume:49 Page:162-175
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Zhu Yaowei,Hu Chuanpu,Lu Ming,Liao Sam,Marini Joseph C.,Yohrling Jennifer,Yeilding Newman,Davis Hugh M.,Zhou Honghui

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference38 articles.

1. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment;Koo;Dermatol Clin,1996

2. Epidemiology of psoriasis: clinical issues;Krueger;J Invest Dermatol,1994

3. Psoriasis;Schon;N Engl J Med,2005

4. Psoriasis;Lebwohl;Lancet,2003

5. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis;Chan;J Exp Med,2006

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension;CPT: Pharmacometrics & Systems Pharmacology;2024-05-29

2. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities;Expert Review of Clinical Pharmacology;2024-04-02

3. Principles of Systemic Therapy;Rook's Textbook of Dermatology;2024-02-20

4. Monoclonal Antibodies: From Structure to Therapeutic Application;Pharmaceutical Biotechnology;2024

5. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial;American Journal of Clinical Dermatology;2023-10-07